Table 1 Chemotherapy-free regimens for adult patients with newly diagnosed Ph + ALL
Study Group or Author | No. of Pts | Age (ys) | CR/CRi | 3 m CMR | Relapse | CNS relapse | Allo-SCT in CR1 | Follow-up (ms) | OS | DFS or EFS | References |
|---|---|---|---|---|---|---|---|---|---|---|---|
GIMEMA LAL2116 D-ALBA | 63 | 54 (24–82) | 98% (62/63) | 29% (17/59) | 15% (9/62) | 6% (4/62) | 39% (24/61) | 53 | 80.7% at 4ys | 75.8% at 4ys | [1] |
BLISSPHALL | 17 | 50 (22–87) | 100% (17/17) | NA | 12% (2/17) | 0 | 23.5% (4/17) | 11.7 (3–24) | All alive | NA | [2] |
University of Colorado Hospital | 14 | 54 (23–72) | 100% (14/14) | NA | 0 | 0 | 21% (3/14) | 15 (4–24) | All alive | No relapse | [3] |
GIMEMA ALLL2820 | 74 | 57 (20–80) | 95% (55/58) | NA | 2% (1/55) | 0 | 0 | 6.1 (0−20.3) | NA | NA | [4] |
MDACC Group | 62 | 56 (20–83) | 98% (39/40) | 84% (46/55) | 10% (6/61) | 5% (3/61) | 2% (1/61) | 17 (2–61) | 89% at 2ys | 77% at 2ys | [5] |
Zhang T, et al. | 13 | 58/34.5 | 100% (13/13) | 100% (13/13) | 8% (1/13) | 0 | 61.5% (8/13) | 7 | 100% At 6ms | 87.5% at 6ms | [6] |
Gong XY, et al. | 31 | 40 (20–66) | 100% (31/31) | 61.3% (19/31) | 0 | 0 | NA | 5.8 | All alive | No relapse | [7] |
Xu GX, et al. | 29 | 45 (19–74) | 100% (25/25) | 82.6% (19/23) | 0 | 0 | 66.7% (16/25) | 8 | 1 death | NA | [8] |